ChAd155 RSV

Drug Profile

ChAd155 RSV

Alternative Names: ChAd155-RSV; GSK3389245A

Latest Information Update: 03 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Protein-vaccines; Respiratory syncytial virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Respiratory syncytial virus infections

Most Recent Events

  • 02 Apr 2017 Efficacy and adverse event data from a phase I trial in Respiratory syncytial virus infections presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017)
  • 27 Sep 2016 Phase-I/II clinical trials in Respiratory syncytial virus infections (In infants, Prevention) in USA (IM) after September 2016 (NCT02927873; EudraCT2016-000117-76)
  • 27 Sep 2016 Phase-I/II clinical trials in Respiratory syncytial virus infections (Prevention, In infants) in Spain (IM) (EudraCT2016-000117-76)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top